Morgan Stanley raised the firm’s price target on Cardinal Health (CAH) to $255 from $245 and keeps an Overweight rating on the shares. The risk reward for Cardinal Health has been updated following the company’s “strong” Q2 results, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $252 from $250 at Baird
- Cardinal Health price target raised to $260 from $250 at UBS
- Cardinal Health price target raised to $260 from $250 at Evercore ISI
- Cardinal Health price target raised to $235 from $222 at Mizuho
- Cardinal Health’s Earnings Call Highlights Broad-Based Upswing